Literature DB >> 33859802

Semisynthetic Derivatives of the Verticillin Class of Natural Products through Acylation of the C11 Hydroxy Group.

Chiraz Soumia M Amrine1,2, Andrew C Huntsman3, Michael G Doyle1, Joanna E Burdette4, Cedric J Pearce5, James R Fuchs3, Nicholas H Oberlies1.   

Abstract

The verticillins, a class of epipolythiodioxopiperazine alkaloids (ETPs) first described 50 years ago with the discovery of verticillin A (1), have gained attention due to their potent activity against cancer cells, noted both in vitro and in vivo. In this study, the complex scaffold afforded through optimized fermentation was used as a feedstock for semisynthetic efforts designed to explore the reactivity of the C11 and C11' hydroxy substituents. Functionality introduced at these positions would be expected to impact not only the potency but also the pharmacokinetic properties of the resulting compound. With this in mind, verticillin H (2) was used as a starting material to generate nine semisynthetic analogues (4-12) containing a variety of ester, carbonate, carbamate, and sulfonate moieties. Likewise, verticillin A succinate (13) was synthesized from 1 to demonstrate the successful application of this strategy to other ETPs. The synthesized compounds and their corresponding starting materials (i.e., 1 and 2) were screened for activity against a panel of melanoma, breast, and ovarian cancer cell lines: MDA-MB-435, MDA-MB-231, and OVCAR3. All analogues retained IC50 values in the nanomolar range, comparable to, and in some cases more potent than, the parent compounds.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33859802      PMCID: PMC8040035          DOI: 10.1021/acsmedchemlett.1c00024

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  39 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 2.  Prodrug approach: An overview of recent cases.

Authors:  Valentina Abet; Fabiana Filace; Javier Recio; Julio Alvarez-Builla; Carolina Burgos
Journal:  Eur J Med Chem       Date:  2016-10-29       Impact factor: 6.514

Review 3.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  A Douglas Kinghorn; Esperanza J Carcache DE Blanco; David M Lucas; H Liva Rakotondraibe; Jimmy Orjala; D Doel Soejarto; Nicholas H Oberlies; Cedric J Pearce; Mansukh C Wani; Brent R Stockwell; Joanna E Burdette; Steven M Swanson; James R Fuchs; Mitchell A Phelps; Lihui Xu; Xiaoli Zhang; Young Yongchun Shen
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

4.  Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.

Authors:  T Tsuruo; T Matsuzaki; M Matsushita; H Saito; T Yokokura
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.

Authors:  Chunwan Lu; Amy V Paschall; Huidong Shi; Natasha Savage; Jennifer L Waller; Maria E Sabbatini; Nicholas H Oberlies; Cedric Pearce; Kebin Liu
Journal:  J Natl Cancer Inst       Date:  2017-01-28       Impact factor: 13.506

Review 6.  Capecitabine: a review.

Authors:  Christine M Walko; Celeste Lindley
Journal:  Clin Ther       Date:  2005-01       Impact factor: 3.393

7.  H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.

Authors:  Amy V Paschall; Dafeng Yang; Chunwan Lu; Jeong-Hyeon Choi; Xia Li; Feiyan Liu; Mario Figueroa; Nicholas H Oberlies; Cedric Pearce; Wendy B Bollag; Asha Nayak-Kapoor; Kebin Liu
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

8.  Synthesis and Anticancer Activity of Epipolythiodiketopiperazine Alkaloids.

Authors:  Nicolas Boyer; Karen C Morrison; Justin Kim; Paul J Hergenrother; Mohammad Movassaghi
Journal:  Chem Sci       Date:  2013-04-01       Impact factor: 9.825

9.  Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.

Authors:  Amrita Salvi; Chiraz Soumia M Amrine; Julia R Austin; KiAundra Kilpatrick; Angela Russo; Daniel Lantvit; Esther Calderon-Gierszal; Zachary Mattes; Cedric J Pearce; Mark W Grinstaff; Aaron H Colby; Nicholas H Oberlies; Joanna E Burdette
Journal:  Mol Cancer Ther       Date:  2020-01       Impact factor: 6.261

10.  Verticillin A Inhibits Leiomyosarcoma and Malignant Peripheral Nerve Sheath Tumor Growth via Induction of Apoptosis.

Authors:  A Zewdu; G Lopez; D Braggio; C Kenny; D Constantino; H K Bid; K Batte; O H Iwenofu; N H Oberlies; C J Pearce; A M Strohecker; D Lev; R E Pollock
Journal:  Clin Exp Pharmacol       Date:  2016-10-24
View more
  3 in total

1.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  Leslie N Aldrich; Joanna E Burdette; Esperanza Carcache de Blanco; Christopher C Coss; Alessandra S Eustaquio; James R Fuchs; A Douglas Kinghorn; Amanda MacFarlane; Brittney K Mize; Nicholas H Oberlies; Jimmy Orjala; Cedric J Pearce; Mitch A Phelps; Liva Harinantenaina Rakotondraibe; Yulin Ren; Djaja Doel Soejarto; Brent R Stockwell; Jack C Yalowich; Xiaoli Zhang
Journal:  J Nat Prod       Date:  2022-02-25       Impact factor: 4.803

Review 2.  Cyclic Dipeptides: The Biological and Structural Landscape with Special Focus on the Anti-Cancer Proline-Based Scaffold.

Authors:  Joanna Bojarska; Adam Mieczkowski; Zyta M Ziora; Mariusz Skwarczynski; Istvan Toth; Ahmed O Shalash; Keykavous Parang; Shaima A El-Mowafi; Eman H M Mohammed; Sherif Elnagdy; Maha AlKhazindar; Wojciech M Wolf
Journal:  Biomolecules       Date:  2021-10-14

3.  Media and strain studies for the scaled production of cis-enone resorcylic acid lactones as feedstocks for semisynthesis.

Authors:  Zeinab Y Al Subeh; Huzefa A Raja; Jennifer C Obike; Cedric J Pearce; Mitchell P Croatt; Nicholas H Oberlies
Journal:  J Antibiot (Tokyo)       Date:  2021-06-21       Impact factor: 3.424

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.